SARC is proud to partner with Sara’s Cure and Rafael Pharmaceuticals for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue. Rafael will begin enrolling patients into the Simon two-stage design trial at sites across the United States.

“Our daughter’s battle with clear cell sarcoma was very eye opening around the lack of treatment options for patients with clear cell sarcoma, largely due to the rarity of the disease,” said Lennie Woods, Founder and Executive Director of Sara’s Cure. “When we learned about Rafael’s dedication to fighting rare diseases, we immediately connected to discuss if devimistat can potentially be a solution in treating this disease. We are so grateful to have a partner like Rafael that truly cares about helping people like our daughter, and reminds our entire community that we are not alone in this fight.”

Woods founded Sara’s Cure after Sara, her teenage daughter, was diagnosed with clear cell sarcoma. Traveling to the top hospitals across the country, Woods and her family discovered how difficult it is to treat this disease, and even once it is successfully treated, it often returns. Clear cell sarcoma is most often found in teens and young adults in their 20s.

“This study is an outstanding example of the value of collaborative efforts among advocacy, biotech, and academia. Recognizing the need to better understand and treat clear cell sarcoma, SARC, as an academic research consortium will leverage the strengths of SARC to assist with this important trial,” said Steven Young, President and CEO of Sarcoma Alliance for Research Collaboration. SARC has been instrumental in assisting with the study design, correlative studies, identifying key sites to run the trial as well as coordinating with Sara’s Cure.

Click here to view full press release.

Back to top